Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Fargnoli, Maria Concetta, Bardazzi, Federico, Bianchi, Luca, Dapavo, Paolo, Fabbrocini, Gabriella, Gisondi, Paolo, Micali, Giuseppe, Offidani, Anna Maria, Pellacani, Giovanni, Skroza, Nevena, Angileri, Rosa Giuseppa, Burlando, Martina, Campanati, Anna, Carrera, Carlo Giovanni, Chiricozzi, Andrea, Conti, Andrea, Simone, Clara De, Di Lernia, Vito, Errichetti, Enzo, Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Lembo, Serena, Loconsole, Francesco, Megna, Matteo, Musumeci, Maria Letizia, Prignano, Francesca, Richetta, Antonio Giovanni, Trovato, Emanuele, Venturini, Marina, Peris, Ketty, Pinton, Piergiacomo Calzavara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219103/
https://www.ncbi.nlm.nih.gov/pubmed/37240650
http://dx.doi.org/10.3390/jcm12103545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219103/
https://www.ncbi.nlm.nih.gov/pubmed/37240650
http://dx.doi.org/10.3390/jcm12103545

Ejemplares similares